Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    TopAbstracts in Renal Cancer 09/03/2008 - (DGNews)
    FDA Investigating Possible Link Between Ezetimibe/Simvastatin and Increased Cancer Risk - (DGNews)
    TopAbstracts in Renal Cancer 08/20/2008 - (DGNews)
    TopAbstracts in Renal Cancer 08/11/2008 - (DGNews)
    Succinate Dehydrogenase Linked to Breast, Thyroid, Renal Cancer Predisposition - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer
    • Targeted Therapies Show Activity as First-Line Treatment of Renal Cell Carcinoma
    • Emerging Therapies and Combination Therapy as the Future of Renal Cell Carcinoma Treatment
    • Utilizing and Improving Prognostic Markers in Determining Best Treatment of Renal Cell Carcinoma
    • New Science and Therapeutic Advances in the Treatment of Renal Cell Carcinoma: A Case Study Review
      Monographs in Renal Cell Carcinoma

      Webcasts/CME archive

       Recent cases - Renal Cancer
        Tongue Metastasis as an Initial Presentation of Renal Cell Carcinoma: A Case Report and Literature Review
        Perirenal Schwannoma: A Case Report
        Surgical Treatment of a Rare Primary Renal Carcinoid Tumor with Liver Metastasis
        Late Pulmonary Metastases of Renal Cell Carcinoma Immediately after Post-Transplantation Immunosuppressive Treatment: A Case Report
        Cold Saline Irrigation of the Renal Pelvis During Radiofrequency Ablation of a Central Renal Neoplasm: A Case Report

        Cases archive
          




        my personal edition > renal cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Results Encouraging with Interferon Alpha Plus Iressa (Gefitinib) or Gleevec (imatinib mesylate) in Metastatic Renal Cell Carcinoma: Presented at AACR-NCI-EORTC

        By Maggie Schwarz

        PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in patients with metastatic renal cell carcinoma, IFN plus Iressa has turned out to be the safer and more effective combination.

        Lead investigator Robert J. Amato, DO, Director, Genitourinary Oncology Center, Methodist Hospital Research Institute, Houston, Texas, United States, presented these results here on November 16th at the International Conference on Molecular Targets and Cancer Therapeutics.

        The conference is organized jointly by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC).

        The researchers are applying a non-randomized alternating schedule of subcutaneous IFN plus Gleevec 600 mg/day and IFN plus Iressa 500 mg/day in patients with progressive metastatic renal cell carcinoma. The cycle is 4 weeks in duration and tumor response assessment involves the Response Evaluation Criteria in Solid Tumors performed every 3 cycles. IFN is dosed at 3 million IU 3 times weekly for 1 week followed by 6 million IU weekly.

        To date, the researchers have treated 10 men and two women, median age of 51 years (range, 25-66 years). All have progressive metastatic renal cell carcinoma.

        Among the eight patients treated with IFN/Iressa, two demonstrated a partial response, one a minor response, and one had stabilization of disease. In four subjects, it is too early to discern a response.

        Adverse effects with IFN/Iressa have consisted of skin rash and diarrhea. With IFN/Gleevec, adverse effects have been skin rash, thrombocytopenia and leucopenia. Both combinations are associated with flu-like syndrome and fatigue, Dr. Amato said.

        Iressa is an inhibitor of epithelial growth factor receptor (EGFR) tyrosine kinase activity. Gleevec is a potent inhibitor of the Abl tyrosine kinase. IFN is an agent used commonly in renal cell carcinoma.

        Dr. Amato concluded that IFN/Iressa can be administered safely with encouraging early anti-tumor activity. IFN/Gleevec can be administered safely with reversible toxicity, with limited anti-tumor activity reported.

        The group is continuing with patient enrollment, treatment, analysis of response and progression-free survival and correlative immunohistochemistry.


        [Presentation title: A Phase II Study of Interferon-Alpha (IFN), Gleevec or Iressa Patients with Metastatic Renal Cell Carcinoma. Abstract A263]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send